A review of antisense oligonucleotides in the treatment of human disease

Drugs of the Future

Volumn 29, Issue 9, 2004, Pages 893-909

  Rubenstein, Marvin ^a,b   Tsui, Paulus ^a   Guinan, Patrick ^a,b,c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; ALICAFORSEN; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; ATL 1102; AVI 14020; AVI 4020; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FENRETINIDE; FOMIVIRSEN; GEM 220; GEM 240; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; INTERFERON; IRINOTECAN; ISIS 104838; ISIS 107248; ISIS 113715; ISIS 14803; ISIS 14838; ISIS 23722; ISIS 301012; ISIS 3521; MBI 1121; MITOXANTRONE; NEUGENE; OBLIMERSEN; OGX 011; PEGINTERFERON; PENICILLIN DERIVATIVE; PUROMYCIN; RESTEN; RETROVIRUS VECTOR; RIBAVIRIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; BASE PAIRING; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CLINICAL TRIAL; DIABETES MELLITUS; DNA VECTOR; DRUG INDUSTRY; DRUG ISOLATION; DRUG TARGETING; GENE ACTIVATION; GENE IDENTIFICATION; GENE REPLICATION; GENE TARGETING; GENE THERAPY; GENETIC RECOMBINATION; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN TARGETING; PROTEOMICS; PROTO ONCOGENE; RESTENOSIS; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VIRUS CULTURE; VIRUS IDENTIFICATION;

EID: 8844258791     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.09.854176     Document Type: Review

References (91)

1. Fleming, A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929, 10: 226-36.
2. A science odyssey; People and discoveries, www.pbs.org/wgbh/aso/databank/ entries/dm28pe.html+Alexander+Fleming+penicillin
3. Isaacs, A., Lindenmann, J. Viral interference. The interferon. Proc Roy Soc Lond (Biol) 1957, 147: 258-67.
4. Allen, D.W., Zamecnik, P.C. The effect of puromycin on rabbit reticulocyte ribosomes. Biochim Biophys Acta 1962, 55: 865-74.
5. Zamecnik, P.C., Stephenson, M.L. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1979, 75: 280-4.
6. Stephenson, M.L., Zamecnik, P.C. Inhibition of Rous sarcoma viral translation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1979, 75: 285-8.
7. Agarwal, S. Preface. In: Antisense Therapeutics. B.A. Teicher (Ed.). Humana Press, Totowa, 1996.
8. Guvakova, M.A., Yakubov, L., Vlodavsky, I., Tonkinson, J.L., Stein, C.A. Phosphorothioate oligonucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995, 270: 2620-7.
9. Rubenstein, M., Mirochnik, Y., Bremer, E., George, D., Frilich, L., Guinan, P. Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate cancer cells. Proc Am Assoc Cancer Res 2002, 43: 590.
10. Marr, J. J. Applications of chemically synthesized and expression of vector ribozymes in human therapeutic applications. IBC Conf Commerc Oligonucleotide-Based Ther. Latest Clin Trials Appl (February 9-10, Coronado) 1995.
11. Santon, J. Oligonucleotide drug development: Improved uptake and delivery. IBC Conf Commerc Oligonucleotide-Based Ther (December 6-7, Coronado) 1993.
12. Fire, A.Z. Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806-11.
13. Yamada, H., Koizumi, S., Kimura, M., Shimizu, N. Reduction of EGF receptor levels in human tumor cells transfected with an antisense RNA expression vector. Exp Cell Res 1989, 184: 90-8.
14. Paulssen, R.H., Paulssen, E.J., Alestrtom, P., Gordeladze, J.O., Gautvik, K.M. Specific antisense RNA inhibition of growth hormone production in differentiated rat pituitary tumour cells. Biochem Biophys Res Commun 1990, 171: 293-300.
15. Stilbach, K., Pollwein, P., Schwab, M., Handgretinger, R., Treuner, J., Niethammer, D., Brucheit, G. Reduction of N-myc expression by antisense RNA is amplified by interferon: Possible involvement of the 2-5A system. Biochem Biophys Res Commun 1990, 170: 1242-8.
16. Kolch, W., Heidecker, G., Lloyd, P., Rapp, U.R. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 1990, 349: 426-8.
17. Mukhopadhyay, T., Tainsky, M., Cavender, A.C., Roth, J.A. Specific inhibition of k-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991, 51: 1744-8.
18. Vleminckx, K., Vakaet, L. Jr., Mareel, M., Fiers, W., Van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66: 107-19.
19. Whitesell, L., Rosolen, A., Neckers, L.M. Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol Cell Biol 1991, 11: 1360-71.
20. Yokoyama, K. Transcriptional regulation of c-myc protooncogene by antisense RNA. In: Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. E. Wickstrom (Ed.). Wiley-Liss, New York, 1991, 35-51.
21. McManaway, M.E., Neckers, L.M., Loke, S.L., Al-Nasser, A.A., Redner, R.L., Shiramizu, B.T., Goldschmidts, W.L., Huber, B.E., Bhatia, K., Magrath, I.T. Tumour-specific inhibition of lymphoma growth by an antisense oligonucleotide. Lancet 1990, 335: 806-11.
22. Rosolen, A., Whitesell, L., Ikegaki, N., Kennett, R.H., Nechers, L.M. Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelial cell line. Cancer Res 1990, 50: 6316-22.
23. Chang, E.H., Miller, P.S., Cuchman, C., Devadas, K., Pirollo, K.F., Ts'o, P.O., Yu, Z.P. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 1991, 30: 8283-6.
24. Melani, C., Rivoltini, L., Parmiani, G., Calabretta, B., Colombo, M.P. Inhibition of proliferation by c-myb antisense oligonucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 1991, 51: 2897-901.
25. Watson, P.H., Pon, R.T., Shiu, R.P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotides identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 1991, 51: 3996-4000.
26. Weigent, D.A., Blalock, J.E., LeBoeuf, R.D. An antisense oligodeoxynucleotide to growth messenger ribonucleic acid inhibits lymphocyte proliferation. Endocrinology 1991, 128: 2053-7.
27. Kitajima, I., Shinohara, T., Bilakovics, J., Brown, D.A., Xu, X., Nerenberg, M. Ablation of transplanted HTLV-1 Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992, 258: 1792-5.
28. Rubenstein, M., Muchnik, S., Dunea, G., Chou, P., Guinan, P. Antisense oligonucleotide treatment of prostate cancer. J Cell Biochem 1993, 17E(Suppl.): 198.
29. Rubenstein, M., Muchnik, S., Dunea, G., Chou, P., Guinan, P. Inoculation of prostatic tumors with antisense oligonucleotides against mRNA encoding growth factors and receptors. In: Recent Advances in Chemotherapy. J. Einhorn, C.E. Nord and S.R. Norrby (Eds.). American Society for Microbiology, Washington, D.C., 1994, 898-9.
30. Kimura, G., Kasuya, J., Giannini, S., Kawachi, M.H., Fujita-Yamaguchi, Y. Inhibition of IGF-II stimulated growth of prostate cancer cells by IGF-1 receptor-specific monoclonal antibody and antisense oligonucleotide of IGF-II messenger RNA. J Urol 1994, 151: 367.
31. Jemal, A., Tiwari, B.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J., Thun, M.J. Cancer statistics 2004. CA Cancer J Clin 2004, 54: 8-29.
32. Rubenstein, M., Guinan, P. A review of various antisense oligonucleotide therapeutic approaches for prostate cancer. Prostate J 2000, 2: 179-88.
33. Geiger, T., Müller, M., Monia, B.P., Fabbro, D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 1997, 3: 1179-85.
34. Lau, Q.C., Brüsselbach, S., Müller, R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998, 16: 1899-902.
35. Balaji, K.C., Koul, H., Mitra, S., Maramag, C., Reddy, P., Menon, M., Malhotra, R.K., Laxmanan, S. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer. Urology 1997, 50: 1007-15.
36. Steiner, M.S., Anthony, C.T., Lu, Y., Holt, J.T. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998, 9: 747-55.
37. Su, Z., Goldstein, N.I., Fisher, P.B. Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc Natl Acad Sci USA 1998, 95: 1764-9.
38. Rubenstein, M., Mirochnik, Y., Chou, P., Guinan, P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth Find Exp Clin Pharmacol 1998, 20: 825-31.
39. Rubenstein, M., Dunea, G., Guinan, P. Growth factor deprivation therapy utilizing antisense oligonucleotides. Drug News Perspect 1994, 7: 517-24.
40. Rubenstein, M., Mirochnik, Y., Chou, P., Guinan, P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996, 62: 194-200.
41. Campbell, M.J., Dawson, M., Koeffler, H.P. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br J Cancer 1998, 77: 739-44.
42. Miyake, H., Tolcher, A., Gleave, M.E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999, 59: 4030-4.
43. Gleave, M., Tolcher, A., Miyake, H., Nelson, C., Brown, B., Beraldi, E., Goldie, J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5: 2891-8.
44. Dorai, T., Olsson, C.A., Katz, A.E., Buttyan, R. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 1997, 32: 246-58.
45. Dorai, T., Goluboff, E.T., Olsson, C.A., Buttyan, R. Development of a hammerhead ribozyme against Bcl-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptosis. Anticancer Res 1997, 17: 3307-12.
46. Lee, C.H., Liu, M., Sie, K.L., Lee, M.S. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res 1996, 16: 1805-11.
47. Gao, A.C., Lou, W., Isaacs, J.T. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorgenicity. Cancer Res 1998, 58: 1391-404.
48. Sementchenko, V.I., Schweinfest, C.W., Papas, T.S., Watson, D.K. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 1998, 17: 2883-8.
49. Zhu, N., Wang, Z. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells. Cancer Res 1999, 58: 1896-902.
50. Nasu, Y., Timme, T.L., Yang, G., Bangma, C.H., Li, L., Ren, C., Park, S.H., DeLeon, M., Wang, J., Thompson T.C. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998, 4: 1062-4.
51. Zheng, J., Rudra-Ganguly, N., Powell, W.C., Roy-Burman, P. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene. Am J Pathol 1999, 155: 115-22.
52. Uhlmann, E., Peyman, A. Antisense oligonucleotides: A new therapeutic principle. Chem Rev 1990, 90: 544-79.
53. Mirabelli, C.K., Bennet, C.F., Anderson, K., Crooke, S.T. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 1991, 6: 647-61.
54. Stein, C.A., Cheng, Y.C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 1993, 261: 1004-12.
55. Miller, P.S., Murray, J.A.H (Eds.). Antisense RNA and DNA. Wiley-Liss, New York, 1992, 241.
56. Crooke, S.T. Progress in oligonucleotide therapeutics. IBC Conf Commerc Oligonucleotide-Based Then Latest Clin Trials Appl (February 9-10, Coronado) 1995.
57. Crooke, S.T. (Ed.). Therapeutic Applications of Oligonucleotides. R.G. Landes Co., Austin, 1995.
58. Galbraith, W.M., Hobson, W.C., Giclas, P.C., Schechter, P.J., Agrawal, S. Complement activation and hemodynamic changes following intravenous administration of phosphorothiate oligonucleotides in the monkey. Antisense Res Develop 1994, 4: 201-6.
59. Kazakov, S.A. Platinated oligonucleotides. IBC Conf Oligonucleotide-Based Then Mol Tools Novel Ther Strategies (May 3-5, Coronado) 1999.
60. De Mesmaeker, A., Waldner, A., Lebreton, J., Hoffmann, P., Fritsch, V., Wold, R.M., Freier, S.M. Amides is a new type of backbone modification in oligonucleotides. Angew Chem Int Eng Ed 1994, 33: 226-9.
61. Altmann, K.-H., Bevierre, M.O., De Mesmaeker, A., Moser, H.E. The evaluation of 2'- and 6'-substituted carbocyclic nucleosides as building blocks for antisense oligonucleotides. Bioorg Med Chem Lett 1995, 5: 431-6.
62. Schmit, C., Bevierre, M.O., De Mesmaeker, A., Altmann, K.-H. The effects of 2'- and 3-alkyl substituents on oligonucleotide hybridization and stability. Bioorg Med Chem Lett 1994, 4: 1969-74.
63. Martin, P. Helv Chim Acta 1995, 78: 486-504.
64. Ravichandran, L.V., Dean, N.M., Marcusson, E.G. Review article. Use of antisense oligonucleotides in functional genomics and target validation. Oligonucleotides 2004, 14: 49-64.
65. Summerton, J., Weller, D. Review article. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucl Acid Drug Develop 1997, 7: 187-95.
66. Summerton, J. Practical solution for targeting and delivering antisense oligos. Antisense technologies. CHI Conf Antisense Technol (June 21-23, San Francisco) 1998.
67. Fluiter, K., Frieden, M., Vreijling, J., Jakobs, M., Rosenbohm, C., Koch, T., Baas, F. The properties of novel generation LNA chemistries in antisense oligonucleotide. Effects on biodistribution and efficacy of tumor growth inhibition in vivo. Proc Am Assoc Cancer Res 2004, 45: Abst 2931.
68. Thrue, C.A., Westergaard, M., Hansen, B., Hansen, H.F., Kjaerulff, S., Oerum, H., Wissenbach, M. New LNA antisense cancer drugs targeting survivin. Proc Am Assoc Cancer Res 2004, 45: Abst 3018.
69. Agrawal, S. Therapeutic potential of mixed-backbone oligonucleotides. IBC Conf Antisense DNA- and RNA-Based Ther (Feb 2-3, Coronado) 1998.
70. Rubenstein, M., Slobodskoy, L., Mirochnik, Y., Guinan, P. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-α or EGFR in the treatment of prostate cancer cell lines. Meth Find Exp Clin Pharmacol 2002, 24: 649-52.
71. Rubenstein, M., Click, R., Lichtor, T., Mirochnik, Y., Chou, P., Guinan, P. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth-α and the epidermal growth factor receptor. Med Oncol 2001, 18: 121-30.
72. Pardridge, W.M. Transcellular drug delivery of antisense oligonucleotide-based therapeutics through the blood brain barrier in vivo. IBC Conf Commerc Oligonucleotide-Based Ther (December 6-7, Coronado) 1993.
73. Mirochnik, Y, Rubenstein, M., Guinan, P. Two constructed antibody derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. Drug Delivery, In press.
74. Rubenstein, M., Mirochnik, Y., Guinan, P. Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. Proc Am Assoc Cancer Res 1996, 37: 303.
75. Rubenstein, M., Mirochnik, Y., Guinan, P. Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. In: Oligonucleotide and Gene Therapy-Based Antisense Therapeutics with New Applications for Genomics. W. Hori and E.M. Nagle (Eds.). IBC Library Series, Southborough 1997, 4.3.1-10.
76. Spitalny, G.L. Targeted delivery of antisense DNA for treatment of hepatitis B viral infection. IBC Conf Commerc Oligonucleotide-Based Ther (December 6-7, Coronado) 1993.
77. Holt, J. Antisense retroviral vectors for gene therapy of breast or prostate cancer. IBC Conf Oligonucleotide Gene Therapy-Based Antisense Ther (February 15-16, Coronado) 1996.
78. Marr, J.J. Application of chemically synthesized and vector delivered ribozymes. IBC Conf Oligonucleotide Gene Therapy Based Antisense Ther (February 15-16, Coronado) 1996.
79. Lee, B.-S., Fujita, M., Ljubimova, J.Y., Holler, E. Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid. Proc Am Assoc Cancer Res 2004, 45: Abst 647.
80. Santhakumaran, L., Thomas, T., Thomas, T.J. Nanoparticle formation in an antisense olignucleotide by polypropylinimine dendrimers: Facilitation of cellular uptake and intracellular stability. Proc Am Assoc Cancer Res 2004, 45: Abst 2938.
81. Pollack, A. An F.D.A. advisory panel rejects 2 cancer drugs. The New York Times, May 4, 2004, C2.
82. Geiger, T., Müller, M., Monia, B., Fabbro, D. Antitumor activity of a c-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 1997, 3: 1179-85.
83. Mewani, R., Tang, W., Rahman, A., Dritschilo, A., Ahmad, I., Kasid, U.N., Gokhale, P.C. Enhanced antitumor activity of liposome-entrapped antsense raf oligonucleotides (LerafAON) in combination with chemotherapeutic agents. Proc Am Assoc Cancer Res 2002, 43: 577.
84. Miyake, H., Monia, B., Gleave, M.E. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus Taxol after castration in the Shionogi tumor model. Int J Cancer 2000, 86: 855-62.
85. Leung, S., Miyake, H., Zellweger, T., Tolcher, A., Gleave, M.E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligonucleotides and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001, 91: 846-50.
86. Rubenstein, M., Slobodskoy, L., Mirochnik, Y., Guinan, P. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol. Med Oncol 2003, 20: 29-35.
87. Chi, K.N., Gleave, M.E., Klasa, R., Nurray, N., Bryce, C., Lopes de Menezes, D.E., D'Aloisio, S., Tolcher, A.W. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone refractory prostate cancer. Clin Cancer Res 2001, 7: 3920-7.
88. Levitt, R., Gleave, M.E., Pollack, M. Bispecific antisense oligonucleotides targeting both IGFBP-2 and IGFBP-5 inhibits growth of U87 glioma cells. Proc Am Assoc Cancer Res 2004, 45: Abst 1427.
89. Signaevsky, M., Beraldi, E., Li, D., Cox, M., Gleave, M.E. IGFBP-2 and IGFBP-5 bispecific antisense oligonucleotides decrease cell survival via induction of apoptosis through alteration of IGF-1 signaling. Proc Am Assoc Cancer Res 2004, 45: Abst 5338.
90. Yamanaka, K., Miyake, H., Zangemeister-wittke, U., Jansen, B., Gleave, M. Novel bispecific antsense oligonucleotides inhibiting both Bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc Am Assoc Cancer Res 2004, 45: Abst 2930.
91. Specificity of RNA interference: Prerequisite for gene research and therapeutics. Discov Med 2003, 3: 18.